Project Details
Description
Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (Penelope B)
| Status | Active |
|---|---|
| Effective start/end date | 3/1/15 → 5/1/25 |
Funding
- NAT'L SURGICAL ADJ BREAST & BOWEL PROJ.
- PFIZER, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.